YMAB(Delisted)
Y-mAbs TherapeuticsยทNASDAQ
--
--(--)
Is YMAB fundamentally strong?
- YMAB scores 0.00/10 on fundamentals and holds a Fair valuation at present. Backed by its -9.40% ROE, -26.03% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 10.71% earnings growth, these metrics solidify its Neutral investment rating.
